Some studies have reported an association between TET2 mutation and favorable outcome of myelodysplastic syndrome (MDS) following treatment with hypomethylating chemotherapy, such as 5′-Aza (25–29), though other studies have not replicated these findings (30). Here, TET2 is linked to myelodysplastic syndrome.